340B Duplicate Discount Prevention

 Move away from "pay and chase" model to front-end validation and prevention.  Recovery-based approaches and platforms still leave manufacturers with substantial amount of heavy lifting through the disputed claims.

Eligibility certified using additional CE provided data. Reliable and validated data with multi-source cross referencing. Additional wholesaler data allows OptivanceX to trace a claim back to its wholesale invoice for accurate eligibility determination, purchase accumulation and dispute resolution.

Platform does not rely on JG/TB modifiers which often are missing or incorrect. A core data transparency gap in the current program is the lack of 340B modifier for Part D drugs and little enforcement for recently established Part B modifier

OptivanceX precisely identifies 340B-eligible claims across both commercial and government-funded programs, preventing duplicate payments before they occur. This high level of accuracy minimizes the need for downstream inquiries and reduces dispute volumes at the source. By enabling early detection and prevention, the platform significantly lowers overall operational burden and ensures cleaner, more reliable claim processing.